A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Bachy, Emmanuel; Le Gouill, Steven; Di Blasi, Roberta; Sesques, Pierre; Manson, Guillaume; Cartron, Guillaume; Beauvais, David; Roulin, Louise; Xavier Gros, François; Thérèse Rubio, Marie; Bories, Pierre; Olivier Bay, Jacques; Castilla Llorente, Cristina; Choquet, Sylvain; Casasnovas, René-Olivier; Mohty, Mohamad; Guidez, Stéphanie; Joris, Magalie; Loschi, Michaël; Carras, Sylvain; Abraham, Julie; Chauchet, Adrien; Drieu La Rochelle, Laurianne; Deau-Fischer, Bénédicte; Hermine, Olivier; Gastinne, Thomas; Jacques Tudesq, Jean; Gat, Elodie; Broussais, Florence; Thieblemont, Catherine; Houot, Roch; Morschhauser, Franck

doi:10.1038/s41591-022-01969-y

Public

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Shared by NobleBlocks on Sep 22, 2022 • 12:00 AM UTC

Authors:

Emmanuel Bachy

Steven Le Gouill

Roberta Di Blasi

Abstract

Abstract Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!